Therapeutic innovation in dermatology continues to accelerate across conditions such as psoriasis, atopic dermatitis, vitiligo, and hidradenitis suppurativa. Yet many promising programs still encounter challenges as they progress toward late-stage development—not because therapies lack efficacy, but because clinical trials may not be designed to fully demonstrate durability of response, long-term safety, and meaningful patient benefit.
For sponsors developing dermatology assets approaching Phase II or Phase III, early strategic decisions around endpoints, safety exposure, durability assessment, and patient experience can determine whether promising early data ultimately translates into regulatory approval and market differentiation.
What’s Inside
This white paper explores key considerations for designing dermatology trials that support late-stage development success, including:
- Why chronic inflammatory dermatoses require a different clinical development playbook
- Designing studies to demonstrate the durability of response and sustained disease control
- Integrating patient-reported outcomes and clinician assessments into endpoint strategy
- Generating the long-term safety data expected for chronic-use therapies
- Strategic decisions around dose selection, comparator strategy, and patient population
- Managing execution risks, placebo variability, and investigator scoring consistency
Download the White Paper
